Literature DB >> 2895379

Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a.

J J Grob, A M Collet, M H Munoz, J J Bonerandi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2895379     DOI： 10.1016/s0140-6736(88)91620-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon.

Authors:  N Mozzanica; A Cattaneo; V Boneschi; L Brambilla; E Melotti; A F Finzi
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide.

Authors:  S A Buechner; M Wernli; T Harr; S Hahn; P Itin; P Erb
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

3.  Treatment of Basal Cell Carcinoma Located in the Head and Neck Region with Intralesional Interferon alpha-2a : Evaluation of Long-Term Follow-Up Results.

Authors:  Seher Bostanci; Pelin Kocyigit; Ayşegül Alp; Cengizhan Erdem; Erbak Gürgey
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

4.  Treatment of basal cell carcinoma with intralesional interferon alpha-2b.

Authors:  M F Healsmith; J Berth-Jones; A Fletcher; R A Graham-Brown
Journal:  J R Soc Med       Date:  1991-09       Impact factor: 18.000

Review 5.  Type I interferons: key players in normal skin and select cutaneous malignancies.

Authors:  Aimen Ismail; Nabiha Yusuf
Journal:  Dermatol Res Pract       Date:  2014-01-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.